{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:56:37Z","timestamp":1791467797233,"version":"4.3.4"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triplet therapy with darolutamide and docetaxel has reshaped the treatment landscape of metastatic castration-sensitive prostate cancer (mCSPC). However, real-world evidence regarding its oncological outcomes and toxicity remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 112 consecutive patients with mCSPC who were treated with triplet therapy. A deep prostate-specific antigen (PSA) response was defined as a PSA level\u00a0&amp;lt;\u00a00.2\u00a0ng\/ml or a\u00a0\u2265\u00a090% decline from baseline. Castration-resistant prostate cancer (CRPC)-free survival was used as the survival endpoint. Clinicopathological factors associated with CRPC-free survival were analysed using a Cox proportional hazards model. Treatment-related adverse events (AEs) were comprehensively documented by type and grade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a median follow-up of 17.1\u00a0months, 15 patients developed CRPC and four died of prostate cancer; 1-year CRPC-free survival and overall survival rates were 89.8% (95% confidence interval, 83.9%\u201396.0%) and 98.8% (96.5%\u2013100%), respectively. A deep PSA response was achieved in 73.2% of patients (PSA nadir &amp;lt;0.2\u00a0ng\/ml) and in 96.4% (PSA\u00a0\u2265\u00a090% decline). In both the univariable and multivariable analyses, no baseline factor was significantly associated with CRPC-free survival. Grade\u00a0\u2265\u00a03 hematologic AEs occurred in 75.0% of patients. Among the 31 patients who discontinued docetaxel, 26 discontinued due to non-hematologic AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Triplet therapy demonstrated substantial clinical activity in real-world patients with mCSPC, with high rates of deep PSA response despite frequent AEs. These findings support the feasibility of triplet therapy in routine practice. Given the substantial toxicity burden, careful patient selection and proactive AE management remain important.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag110","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:21:40Z","timestamp":1783624900000},"page":"1255-1263","source":"Crossref","is-referenced-by-count":0,"title":["Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study"],"prefix":"10.1093","volume":"56","author":[{"given":"Ibuki","family":"Tsuru","sequence":"first","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-4294","authenticated-orcid":false,"given":"Satoru","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-2874","authenticated-orcid":false,"given":"Taketo","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Urology, International University of Health and Welfare Ichikawa Hospital , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyorin University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Jichi Medical University , Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Hoshina","sequence":"additional","affiliation":[{"name":"Department of Urology, Jichi Medical University , Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Obinata","sequence":"additional","affiliation":[{"name":"Department of Urology, Nihon University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Koshiba","sequence":"additional","affiliation":[{"name":"Department of Urology, Shinshu University School of Medicine , Nagano ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Shiozaki","sequence":"additional","affiliation":[{"name":"Department of Urology, Shinshu University School of Medicine , Nagano ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Urology, The Institute of Medical Science, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kano","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Metropolitan Bokutoh Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Metropolitan Bokutoh Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Suda","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fraternity Memorial Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fraternity Memorial Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Musashino Red Cross Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The University of Tokyo Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[{"name":"Biostatistics Section, Department of Data Science, Center of Clinical Sciences, National Center for Global Health and Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimpei","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kamei","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Kakutani","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Niimi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Metropolitan Tama Medical Center , Fuchu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, Musashino Red Cross Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nishimatsu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fraternity Memorial Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Metropolitan Bokutoh Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Urology, The Institute of Medical Science, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The University of Tokyo Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Shinshu University School of Medicine , Nagano ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Nihon University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Fujimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Jichi Medical University , Tochigi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Urology, Kyorin University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9841-0857","authenticated-orcid":false,"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2026100809072211500_ref1","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur Urol Focus"},{"key":"2026100809072211500_ref2","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"2026100809072211500_ref3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"New Engl J Med"},{"key":"2026100809072211500_ref4","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026100809072211500_ref5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43018-023-00692-y","article-title":"Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping","volume":"5","author":"Warner","year":"2024","journal-title":"Nat Cancer"},{"key":"2026100809072211500_ref6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/iju.15647","article-title":"Triplet therapy for metastatic castration-sensitive prostate cancer: rationale and clinical evidence","volume":"32","author":"Suzuki","year":"2025","journal-title":"Int J Urol"},{"key":"2026100809072211500_ref7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur Urol"},{"key":"2026100809072211500_ref8","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026100809072211500_ref9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/cancers17020205","article-title":"An updated systematic review and network meta-analysis of first-line triplet vs. doublet therapies for metastatic hormone-sensitive prostate cancer","volume":"17","author":"Matsukawa","year":"2025","journal-title":"Cancers"},{"key":"2026100809072211500_ref10","doi-asserted-by":"publisher","first-page":"e70029","DOI":"10.1002\/cam4.70029","article-title":"Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: phase 3 ARASENS subgroup analysis","volume":"13","author":"Uemura","year":"2024","journal-title":"Cancer Med"},{"key":"2026100809072211500_ref11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jjco\/hyae098","article-title":"Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study","volume":"54","author":"Urabe","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2026100809072211500_ref12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.prnil.2024.11.003","article-title":"Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study","volume":"13","author":"Urabe","year":"2025","journal-title":"Prostate Int"},{"key":"2026100809072211500_ref13","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1007\/s11255-025-04465-7","article-title":"Short-term outcomes of triplet therapy in metastatic hormone-sensitive prostate cancer in older adults: a retrospective, single-center real-world cohort study","volume":"57","author":"Usui","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"2026100809072211500_ref14","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/iju.70154","article-title":"Preliminary report on the efficacy and safety of triplet therapy in patients with metastatic hormone-sensitive prostate cancer: YUSHIMA study","volume":"32","author":"Yasuda","year":"2025","journal-title":"Int J Urol"},{"key":"2026100809072211500_ref15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.clgc.2023.12.018","article-title":"Real-world evidence of triplet therapy in metastatic hormone-sensitive prostate cancer: an Austrian multicenter study","volume":"22","author":"Kafka","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2026100809072211500_ref16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2026100809072211500_ref17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026100809072211500_ref18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"2026100809072211500_ref19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","article-title":"Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: analyses of the randomized phase 3 ARASENS study","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"key":"2026100809072211500_ref20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2024.05.010","article-title":"Therapy optimization in the management of metastatic hormone-sensitive prostate cancer: insights from the ARASENS study","volume":"86","author":"Merseburger","year":"2024","journal-title":"Eur Urol"},{"key":"2026100809072211500_ref21","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/10\/1255\/68741051\/hyag110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/10\/1255\/68741051\/hyag110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:07:29Z","timestamp":1791464849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/10\/1255\/8729345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,9]]},"published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag110","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,9]]}}}